Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/ml and 10 ng/ml

Journal of the Canadian Urological Association

Volumn 1, Issue 4, 2007, Pages 377-381

  Bolduc, Stéphane ^a   Lacombe, Louis ^a   Naud, Alain ^a   Grégoire, Mireille ^a   Fradet, Yves ^a   Tremblay, Roland R ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651206765     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.444     Document Type: Article

References (19)

1. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-1455.
2. Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med1985;312:338-343.
3. Lizana J, Moberg PJ, Eneroth P. Beta2-microglobulin, carcinoembryonic antigen and prostatic acid phosphatase in split ejaculates and urine voided before and after massage of the prostate. Arch Androl 1983;11:225-232.
4. Malavaud B, Salama G, Miedouge M, et al. Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy. Prostate 1998;34:23-28.
5. Iwakiri J, Granbois K, Wehner N, et al. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993;149:783-786.
6. Takayama TK, Vessella RL, Brawer MK, et al. Urinary prostate specific antigen levels after radical prostatectomy. J Urol 1994;151:82-87.
7. DeVere White RW, Meyers FJ, Soares SS., et al. Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol 1992; 147:947-951.
8. Breul J, Pickl U, Hartung R. Prostate-specific antigen in urine. Eur Urol 1994;26:18-21.
9. Breul J, Pickl U, Schaff J. Extraprostatic production of prostate specific antigen is under hormonal control. J Urol 1997;157:212-213.
10. Pannek J, Rittenhouse HG, Evans CC, et al. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 1997;50:715-721.
11. Tremblay J, Frenette G, Tremblay RR, et al. Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 1987;10:235-423.
12. Irani J, Levillain P, Goujon JM, et al. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997;157:1301-1303.
13. Irani J, Millet C, Levillain P, et al. Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng/mL. J Urol 1997;157:185-188.
14. Tremblay RR, Dubé JY. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 1974;10:599-605.
15. Irani J, Millet C, Levillain P, et al. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer. Eur Urol 1996;29:407-412.
16. Uchijima Y, Yoshida K, Saitoh H. [Significance of prostatic acid phosphatase, gammaseminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases]. Hinyokika Kiyo 1991;37:1255.
17. Hillenbrand M, Bastian M, Steiner M, et al. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Anticancer Res 2000;20:4995-4996.
18. Pejcic T, Hadzi-Djokic J, Acimovic M, et al. Urinary prostate specific antigen: is the clinical use likely? Acta Chir Iugosl 2005;52:69-74.
19. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.